TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01120470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
Study: NCT04109807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: ozone exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: ozone exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FA
Description: Filtered air exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FA
Description: Filtered air exposure
Study: NCT03076216

Intervention type: DEVICE
Group type: OTHER
Intervention: OncoSil™
Description: The implantation of OncoSil™ under EUS
Study: NCT01884506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution
Description: labeled iron as ferrous sulfate (6mg/test meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution
Description: labeled iron as ferrous sulfate (6mg/test meal)
Study: NCT02202161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Study: NCT01860677

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fisher Wallace Cranial Stimulator
Description: The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
Study: NCT04460560

Intervention type: DRUG
Group type: OTHER
Intervention: Terlipressin
Description: For the first dose of terlipressin, each vial will be reconstituted with 5 mL of sterile 0.9% sodium chloride solution and administered intravenously as a bolus injection and given over 1 minute at a dose of 0.5 mg.~For continuous infusion, the dose of terlipressin is to be dissolved in 0.9% sodium chloride solution and infused with a pump
Study: NCT05200000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SygeLIX-Coll-T
Description: Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.
Study: NCT00670163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Partner Therapy (EPT)
Description: EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Partner Therapy (EPT)
Description: EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communidades Positivas (CPOS)
Description: The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communidades Positivas (CPOS)
Description: The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will consist of usual care for STIs.
Study: NCT04395144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Prone Positioning
Description: Patients will receive instruction to remain in prone position as long and as often as possible, up to 16h/24h

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients will not receive any special instructions with regards to proning.
Study: NCT01639196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassion writing
Description: Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-efficacy writing
Description: Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
Study: NCT01884506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution and ascorbic acid
Description: labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled iron solution and ascorbic acid
Description: labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
Study: NCT03118856

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of Histology
Description: The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC

Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of Histology
Description: The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
Study: NCT02512874

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation
Description: Measures of frailty taken before and after pulmonary rehabilitation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamometer
Description: Grip Test

Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA
Description: Body Composition Testing

Intervention type: OTHER
Group type: OTHER
Intervention: Gait Speed Test
Description: 15 foot walk test

Intervention type: DEVICE
Group type: OTHER
Intervention: Activity Monitor
Description: Measures energy expenditure and activity

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
Study: NCT02026739

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high supplemental oxygen concentration (conventional)
Description: high supplemental oxygen concentration would be used during the surgery
Study: NCT04826432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide 0.9 MG/ML
Description: 0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline water
Description: 0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
Study: NCT01336764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal and breathing retraining
Description: They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Unguided listening to radio/music.
Study: NCT01357733

Intervention type: OTHER
Group type: OTHER
Intervention: Early interim FDG PET/CT after 1 cycle of R-CHOP
Description: FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
Study: NCT04873505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: troches
Description: Take one troche after each meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: troches
Description: Take one troche after each meal.
Study: NCT03962010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G6
Description: long acting anti-diabetic drug
Study: NCT02202161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
Study: NCT04022291

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humulin ®70/30
Description: Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocon Insulin 70/30
Description: Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.
Study: NCT01614405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC/LPV/r
Description: one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
Study: NCT01285999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: Everolimus-eluting Coronary Stent Drug-eluting Stent (DES) implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS Liberté Coronary Stent System
Description: Paclitaxel-eluting Coronary Stent Drug-eluting Stent (DES) implantation
Study: NCT03702777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8302
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT00772889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A
Description: One intramuscularly injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Fluarix™
Description: One intramuscularly injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' Fluarix™
Description: One intramuscularly injection at Day 0
Study: NCT03644589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg,Given intravenous (IV) infusion, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
Study: NCT03962010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G6
Description: long acting anti-diabetic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-G6
Description: long acting anti-diabetic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control
Study: NCT02028494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Two dosages comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Two dosages comparison
Study: NCT02378792

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vagus Nerve Stimulation
Description: Vagus Nerve Stimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Vagus Nerve Stimulator
Study: NCT01929798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable Artificial Pancreas
Description: The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
Study: NCT02300688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: administration of 1 time administration of the test drug (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: administration of 1 time administration of the test drug (Treatment A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: administration of 1 time administration of the reference drug (Treatment B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: administration of 1 time administration of the reference drug (Treatment B)
Study: NCT03118258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Pap smear' arm
Description: Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Self-collected vaginal swab for HPV testing + pap smear triage' arm
Description: Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason.
Study: NCT01906008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Test
Description: Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sensory Test
Description: Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
Study: NCT00740831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin
Description: solution for injection
Study: NCT01830972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-ER 500 mg
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-ER 500 mg
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-IR 500 mg
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA-IR 500 mg
Description: oral capsules
Study: NCT02777801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti-HBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti-HBV
Study: NCT01931124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Training
Study: NCT03956732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein (high)
Description: High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein (high)
Description: High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: One daily tablet containing 20 μg of vitamin D3, cholecalciferol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: One daily tablet containing 20 μg of vitamin D3, cholecalciferol.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk Protein (medium)
Description: Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein (medium)
Description: Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
Study: NCT05549570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
Study: NCT03183076

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified adkins diet
Description: Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy without diet
Description: Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet